Biote price target lowered to $8 from $12 at Craig-Hallum

Craig-Hallum analyst Alex Fuhrman lowered the firm’s price target on Biote (BTMD) to $8 from $12 and keeps a Buy rating on the shares. The firm says Biote reported slightly lower-than-expected Q4 results and guided to lower-than-expected 2025 results, with the main culprit being disruption from new decision support software that was rolled out to Biote’s clinical network late last year.